q © biopharmalynx 1.3 É r Ê 2 ïz Ï ¦ ¡ < p t · 2012-11-06 · 31 7 ´ 2 j ¦ _ ¯ À ¡...
Post on 19-Jul-2020
0 Views
Preview:
TRANSCRIPT
30
BiopharmaLynx 1.3
8 105
32
UPLC®/MS
E
BiopharmaLynxTM
MSE
Trastuzumab
ACQUITY UPLC® BEH300 C18 1.7µm
2.1*150mm
Synapt® G2 HDMS
Endoproteinase Lys-C Iodoacetamide
RapiGestTM
Waters p/n 186001861
Lys-C
RapiGest
LC/MSE
BiopharmaLynx Trastuzumab
1 1
1:K1-1:K4
1 1:K1-1:K4
10657.12Da MH+
1C MSE
MSE
1:K1 1:K4
b/y
7019.27Da 1/y39-2/y24 10431.19Da 1/y39-2/
y56
1. 1:K1-1:K4 A UPLC/MS B
C BiopharmaLynx D MSE
31
1:K14-1:K13 SFNRGEC=SCDK
BiopharmaLynx
2:K14-4:K14
1
BiopharmaLynx
Scrambled
Disuldes
1:K13-2:K16 1:K14-2:K16
1:K7-2:K21
1:K7-2:K21
3A
Synapt G2
3B
1. 1:K1-1:K4 A UPLC/MS B
C BiopharmaLynx D MSE
3. A)BiopharmaLynx 1:K13-2:K16,1:K7-2:K21,1:K14-2:K16 B 1:K13-2:K16
2.
!
(UPLC/MSE
BiopharmaLynx1.3 )
Lys-C
top related